# Inspire Medical Systems, Inc.: financial statements, quarterly

INSP · NYSE · CIK 1609550 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/insp.md) · [Financials](/companies/insp/financials.md) · [Filings](/companies/insp/filings.md) · [Insiders](/companies/insp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/insp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [153](/filings/0001609550-24-000053.md) | [193 d](/filings/0001609550-26-000016.md) | [164](/filings/0001609550-25-000020.md) | [196](/filings/0001609550-25-000032.md) | [203](/filings/0001609550-25-000053.md) | [240 d](/filings/0001609550-26-000016.md) | [201](/filings/0001609550-26-000023.md) | [217](/filings/0001609550-26-000047.md) | [225](/filings/0001609550-25-000053.md) | [269 d](/filings/0001609550-26-000016.md) | [205](/filings/0001609550-26-000023.md) | [201](/filings/0001609550-26-000047.md) |
| Cost of revenue | $m | [24.4](/filings/0001609550-24-000053.md) | [28.1 d](/filings/0001609550-26-000016.md) | [24.8](/filings/0001609550-25-000020.md) | [29.8](/filings/0001609550-25-000032.md) | [32.4](/filings/0001609550-25-000053.md) | [36.0 d](/filings/0001609550-26-000016.md) | [30.7](/filings/0001609550-26-000023.md) | [34.7](/filings/0001609550-26-000047.md) | [31.8](/filings/0001609550-25-000053.md) | [36.1 d](/filings/0001609550-26-000016.md) | [27.7](/filings/0001609550-26-000023.md) | [29.1](/filings/0001609550-26-000047.md) |
| Gross profit | $m | [129](/filings/0001609550-24-000053.md) | [164 d](/filings/0001609550-26-000016.md) | [139](/filings/0001609550-25-000020.md) | [166](/filings/0001609550-25-000032.md) | [171](/filings/0001609550-25-000053.md) | [204 d](/filings/0001609550-26-000016.md) | [171](/filings/0001609550-26-000023.md) | [182](/filings/0001609550-26-000047.md) | [193](/filings/0001609550-25-000053.md) | [233 d](/filings/0001609550-26-000016.md) | [177](/filings/0001609550-26-000023.md) | [171](/filings/0001609550-26-000047.md) |
| Research and development | $m | [29.1](/filings/0001609550-24-000053.md) | [31.1 d](/filings/0001609550-26-000016.md) | [28.9](/filings/0001609550-25-000020.md) | [28.9](/filings/0001609550-25-000032.md) | [26.1](/filings/0001609550-25-000053.md) | [30.3 d](/filings/0001609550-26-000016.md) | [27.8](/filings/0001609550-26-000023.md) | [26.2](/filings/0001609550-26-000047.md) | [24.2](/filings/0001609550-25-000053.md) | [24.9 d](/filings/0001609550-26-000016.md) | [25.8](/filings/0001609550-26-000023.md) | [24.7](/filings/0001609550-26-000047.md) |
| Selling, general and administrative | $m | not reported | not reported | [126](/filings/0001609550-25-000020.md) | [132](/filings/0001609550-25-000032.md) | [130](/filings/0001609550-25-000053.md) | [142 d](/filings/0001609550-26-000016.md) | [144](/filings/0001609550-26-000023.md) | [160](/filings/0001609550-26-000047.md) | [159](/filings/0001609550-25-000053.md) | [162 d](/filings/0001609550-26-000016.md) | [152](/filings/0001609550-26-000023.md) | [147](/filings/0001609550-26-000047.md) |
| Operating income | $m | [(13.5)](/filings/0001609550-24-000053.md) | [9.3 d](/filings/0001609550-26-000016.md) | [(15.2)](/filings/0001609550-25-000020.md) | [5.1](/filings/0001609550-25-000032.md) | [14.3](/filings/0001609550-25-000053.md) | [31.9 d](/filings/0001609550-26-000016.md) | [(1.5)](/filings/0001609550-26-000023.md) | [(3.3)](/filings/0001609550-26-000047.md) | [9.6](/filings/0001609550-25-000053.md) | [46.1 d](/filings/0001609550-26-000016.md) | [(1.1)](/filings/0001609550-26-000023.md) | [(0.5)](/filings/0001609550-26-000047.md) |
| Interest expense | $m | [0.0](/filings/0001609550-23-000063.md) | [0.0 d](/filings/0001609550-24-000016.md) | not reported | [0.0](/filings/0001609550-25-000032.md) | [0.0](/filings/0001609550-25-000053.md) | [0.0 d](/filings/0001609550-26-000016.md) | not reported | [0.0](/filings/0001609550-25-000032.md) | [0.0](/filings/0001609550-25-000053.md) | [0.1 d](/filings/0001609550-26-000016.md) | not reported | not reported |
| Income tax | $m | [0.3](/filings/0001609550-24-000053.md) | [0.5 d](/filings/0001609550-26-000016.md) | [0.7](/filings/0001609550-25-000020.md) | [1.1](/filings/0001609550-25-000032.md) | [1.8](/filings/0001609550-25-000053.md) | [1.4 d](/filings/0001609550-26-000016.md) | [1.2](/filings/0001609550-26-000023.md) | [1.3](/filings/0001609550-26-000047.md) | [3.6](/filings/0001609550-25-000053.md) | [(85.8) d](/filings/0001609550-26-000016.md) | [13.7](/filings/0001609550-26-000023.md) | [2.8](/filings/0001609550-26-000047.md) |
| Net income | $m | [(8.5)](/filings/0001609550-24-000053.md) | [14.8 d](/filings/0001609550-26-000016.md) | [(10.0)](/filings/0001609550-25-000053.md) | [9.8](/filings/0001609550-25-000053.md) | [18.5](/filings/0001609550-25-000053.md) | [35.2 d](/filings/0001609550-26-000016.md) | [3.0](/filings/0001609550-26-000047.md) | [(3.6)](/filings/0001609550-26-000047.md) | [9.9](/filings/0001609550-25-000053.md) | [136 d](/filings/0001609550-26-000016.md) | [(11.3)](/filings/0001609550-26-000047.md) | [0.3](/filings/0001609550-26-000047.md) |
| Diluted EPS | $ per share | [(0.29)](/filings/0001609550-24-000053.md) | not reported | [(0.34)](/filings/0001609550-25-000020.md) | [0.32](/filings/0001609550-25-000032.md) | [0.60](/filings/0001609550-25-000053.md) | not reported | [0.10](/filings/0001609550-26-000023.md) | [(0.12)](/filings/0001609550-26-000047.md) | [0.34](/filings/0001609550-25-000053.md) | not reported | [(0.39)](/filings/0001609550-26-000023.md) | [0.01](/filings/0001609550-26-000047.md) |
| Basic EPS | $ per share | [(0.29)](/filings/0001609550-24-000053.md) | not reported | [(0.34)](/filings/0001609550-25-000020.md) | [0.33](/filings/0001609550-25-000032.md) | [0.62](/filings/0001609550-25-000053.md) | not reported | [0.10](/filings/0001609550-26-000023.md) | [(0.12)](/filings/0001609550-26-000047.md) | [0.34](/filings/0001609550-25-000053.md) | not reported | [(0.39)](/filings/0001609550-26-000023.md) | [0.01](/filings/0001609550-26-000047.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [330](/filings/0001609550-23-000063.md) | [186](/filings/0001609550-25-000011.md) | [175](/filings/0001609550-24-000026.md) | [188](/filings/0001609550-24-000044.md) | [148](/filings/0001609550-24-000053.md) | [150](/filings/0001609550-26-000016.md) | [53.9](/filings/0001609550-25-000020.md) | [107](/filings/0001609550-25-000032.md) | [113](/filings/0001609550-25-000053.md) | [105](/filings/0001609550-26-000047.md) | [98.9](/filings/0001609550-26-000023.md) | [128](/filings/0001609550-26-000047.md) |
| Current assets | $m | [570](/filings/0001609550-23-000063.md) | [594](/filings/0001609550-25-000011.md) | [572](/filings/0001609550-24-000026.md) | [607](/filings/0001609550-24-000044.md) | [583](/filings/0001609550-24-000053.md) | [631](/filings/0001609550-26-000016.md) | [572](/filings/0001609550-25-000020.md) | [573](/filings/0001609550-25-000032.md) | [586](/filings/0001609550-25-000053.md) | [584](/filings/0001609550-26-000047.md) | [567](/filings/0001609550-26-000023.md) | [609](/filings/0001609550-26-000047.md) |
| Total assets | $m | [639](/filings/0001609550-23-000063.md) | [677](/filings/0001609550-25-000011.md) | [686](/filings/0001609550-24-000026.md) | [728](/filings/0001609550-24-000044.md) | [796](/filings/0001609550-24-000053.md) | [808](/filings/0001609550-26-000016.md) | [731](/filings/0001609550-25-000020.md) | [802](/filings/0001609550-25-000032.md) | [808](/filings/0001609550-25-000053.md) | [907](/filings/0001609550-26-000047.md) | [911](/filings/0001609550-26-000023.md) | [926](/filings/0001609550-26-000047.md) |
| Current liabilities | $m | [70.0](/filings/0001609550-23-000063.md) | [78.1](/filings/0001609550-25-000011.md) | [72.2](/filings/0001609550-24-000026.md) | [65.7](/filings/0001609550-24-000044.md) | [74.3](/filings/0001609550-24-000053.md) | [88.5](/filings/0001609550-26-000016.md) | [63.5](/filings/0001609550-25-000020.md) | [93.4](/filings/0001609550-25-000032.md) | [111](/filings/0001609550-25-000053.md) | [96.1](/filings/0001609550-26-000047.md) | [89.4](/filings/0001609550-26-000023.md) | [71.2](/filings/0001609550-26-000047.md) |
| Total liabilities | $m | [95.3](/filings/0001609550-23-000063.md) | [104](/filings/0001609550-25-000011.md) | [96.8](/filings/0001609550-24-000026.md) | [90.3](/filings/0001609550-24-000044.md) | [99.6](/filings/0001609550-24-000053.md) | [119](/filings/0001609550-26-000016.md) | [95.1](/filings/0001609550-25-000020.md) | [124](/filings/0001609550-25-000032.md) | [141](/filings/0001609550-25-000053.md) | [126](/filings/0001609550-26-000047.md) | [119](/filings/0001609550-26-000023.md) | [100](/filings/0001609550-26-000047.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [544](/filings/0001609550-24-000053.md) | [573](/filings/0001609550-26-000016.md) | [589](/filings/0001609550-25-000053.md) | [638](/filings/0001609550-25-000053.md) | [697](/filings/0001609550-25-000053.md) | [690](/filings/0001609550-26-000047.md) | [636](/filings/0001609550-26-000047.md) | [678](/filings/0001609550-26-000047.md) | [666](/filings/0001609550-25-000053.md) | [781](/filings/0001609550-26-000047.md) | [792](/filings/0001609550-26-000047.md) | [826](/filings/0001609550-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3.6 d](/filings/0001609550-24-000053.md) | [17.3 d](/filings/0001609550-26-000016.md) | [8.9](/filings/0001609550-25-000020.md) | [(0.1) d](/filings/0001609550-25-000032.md) | [52.3 d](/filings/0001609550-25-000053.md) | [69.2 d](/filings/0001609550-26-000016.md) | [(6.7)](/filings/0001609550-26-000023.md) | [2.7 d](/filings/0001609550-26-000047.md) | [68.5 d](/filings/0001609550-25-000053.md) | [52.5 d](/filings/0001609550-26-000016.md) | [12.8](/filings/0001609550-26-000023.md) | [23.2 d](/filings/0001609550-26-000047.md) |
| Capital expenditure | $m | [7.0 d](/filings/0001609550-24-000053.md) | [8.0 d](/filings/0001609550-26-000016.md) | [11.7](/filings/0001609550-25-000020.md) | [12.4 d](/filings/0001609550-25-000032.md) | [8.0 d](/filings/0001609550-25-000053.md) | [7.0 d](/filings/0001609550-26-000016.md) | [8.4](/filings/0001609550-26-000023.md) | [9.0 d](/filings/0001609550-26-000047.md) | [10.4 d](/filings/0001609550-25-000053.md) | [10.7 d](/filings/0001609550-26-000016.md) | [9.7](/filings/0001609550-26-000023.md) | [9.2 d](/filings/0001609550-26-000047.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001609550-25-000020.md) | [0.0 d](/filings/0001609550-25-000032.md) | [0.0 d](/filings/0001609550-25-000053.md) | [0.0 d](/filings/0001609550-26-000016.md) | [75.0](/filings/0001609550-26-000023.md) | [0.0 d](/filings/0001609550-26-000047.md) | [50.0 d](/filings/0001609550-25-000053.md) | [50.0 d](/filings/0001609550-26-000016.md) | [0.0](/filings/0001609550-26-000023.md) | [0.0 d](/filings/0001609550-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.2](/filings/0001609550-23-000063.md) | [29.1](/filings/0001609550-24-000026.md) | [29.2](/filings/0001609550-24-000044.md) | [29.4](/filings/0001609550-24-000053.md) | [29.6](/filings/0001609550-25-000020.md) | [30.4](/filings/0001609550-25-000032.md) | [30.6](/filings/0001609550-25-000053.md) | [30.3](/filings/0001609550-26-000023.md) | [29.5](/filings/0001609550-26-000047.md) | [29.6](/filings/0001609550-25-000053.md) | [28.7](/filings/0001609550-26-000023.md) | [28.9](/filings/0001609550-26-000047.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,910,375 at 2026-07-30, from the cover of the [10-Q filed 2026-08-03](/filings/0001609550-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.